Small cell lung cancer (SCLC) is the most aggressive lung cancer subtype and little progress has been made in understanding the molecular mechanisms causing this devastating disease. No mechanistic explanation exists for a central clinical hallmark: While SCLC typically presents with initial sensitivity against chemotherapy, the disease almost inevitably relapses. Recent discoveries in SCLC genomics and transcriptomics have now provided first mechanistic insight into the biology of this deadly disease. 

Latest Publications

  • Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA
    Hudecova I, Smith CG, Hänsel-Hertsch R, Chilamakuri C, Morris JA, Vijayaraghavan A, Heider K, Chandrananda D, Cooper WN, Gale D, Garcia-Corbacho J, Pacey SC, Baird R, Rosenfeld N, Mouliere F. 
    Genome Res. 2021 Dec 20
  • Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma
    Johanna A Seier, Julia Reinhardt, Kritika Saraf, Susanna S Ng, Julian P Layer, Dillon Corvino, Kristina Althoff, Frank A Giordano, Alexander Schramm, Matthias Fischer, Michael Hölzel
    Journal for ImmunoTherapy of Cancer. 2021 May 20
  • Ferroptosis response segregates small cell lung cancer (SCLC) neuroendocrine subtypes.
    Christina M. Bebber, Emily S. Thomas, Jenny Stroh, Zhiyi Chen, Ariadne Androulidaki, Anna Schmitt, Michaela N. Höhne, Lukas Stüker, Cleidson de Pádua Alves, Armin Khonsari, Marcel A. Dammert, Fatma Parmaksiz, Hannah L. Tumbrink, Filippo Beleggia, Martin L. Sos, Jan Riemer, Julie George, Susanne Brodesser, Roman K. Thomas, H. Christian Reinhardt & Silvia von Karstedt.
    Nature Communications. 2021 Apr 6, volume 12.
    Article number: 2048 (2021)